TENX As previously announced, Tenax Therapeutics, Inc. (the "Company") is enriching its LEVEL-2 clinical trial based on key learnings from i
TENX As previously announced, Tenax Therapeutics, Inc. (the "Company") is enriching its LEVEL-2 clinical trial based on key learnings from its recently completed Phase 3 LEVEL trial of TNX-103 in PH-HFpEF. The Company intends to amend LEVEL-2 enrollment criteria, as set forth in the attached Investor Presentation. To m